5 Stocks Racking Up Monster Gains

2. Organon & Co. (NYSE:OGN)

Organon soared to a new 52-week high on Monday, as investors gobbled up shares after the company officially confirmed its planned $11.75-billion merger with Sun Pharmaceuticals.

In intra-day trading, the stock climbed to its highest price of $13.24 before trimming gains to finish the session just up by 16.87 percent at $13.16 apiece.

In a joint statement, Organon & Co. (NYSE:OGN) said that Sun Pharma is set to acquire all its outstanding shares at $14 apiece, in an all-cash transaction, in line with the latter’s strategy of growing its innovative medicines business.

The transaction officially secured the green light of both firms’ board of directors and is now up for approval by the shareholders.

“Following a comprehensive review of strategic alternatives, our board determined that this all‑cash transaction offers compelling and immediate value to Organon stockholders. We believe Sun Pharma is well-positioned to support Organon’s businesses, employees, and patients globally, and to further advance our commitment to delivering impactful medicines and solutions,” said Organon & Co. (NYSE:OGN) Executive Chairman Carrie Cox.

The transaction is expected to close in early 2027, subject to other customary closing conditions.

Organon & Co. (NYSE:OGN) is a global leader in women’s health. It was formed through a spinoff from Merck, known as MSD outside of the United States and Canada, in 2021.